Below are the financial statements of ADMA Biologics, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.
| All figures in millions of USD | 2024 as of 2024-12-31 | 2023 as of 2023-12-31 |
|---|---|---|
| Assets | — | — |
| Current assets | — | — |
| Cash and cash equivalents | 103.15a | 51.35a |
| Accounts receivable, net | 50a | 27.42a |
| Inventories | 170.24a | 172.91a |
| Prepaid expenses and other current assets | 8.03a | 5.33a |
| Total current assets | 331.41a | 257.01a |
| Property and equipment, net | 54.71a | 53.84a |
| Intangible assets, net | 0.46a | 0.5a |
| Goodwill | 3.53a | 3.53a |
| Deferred tax assets, net | 84.28a | 0a |
| Right-of-use assets | 8.63a | 9.64a |
| Deposits and other assets | 5.66a | 4.67a |
| Total assets | 488.68a | 329.18a |
| Liabilities and stockholders’ equity | — | — |
| Current liabilities | — | — |
| Accounts payable | 20.22a | 15.66a |
| Accrued expenses and other current liabilities | 33.96a | 32.92a |
| Current portion of deferred revenue | 0.14a | 0.18a |
| Current portion of lease obligations | 1.22a | 1.05a |
| Total current liabilities | 55.54a | 49.81a |
| Senior notes payable, net of discount | 72.34a | 130.59a |
| Deferred revenue, net of current portion | 1.55a | 1.69a |
| End of term fee | 1.31a | 1.69a |
| Lease obligations, net of current portion | 8.56a | 9.78a |
| Other non-current liabilities | 0.36a | 0.42a |
| Total liabilities | 139.66a | 193.98a |
| Stockholders’ equity | — | — |
| Preferred stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding | 0a | 0a |
| Common stock - voting, $0.0001 par value, 300,000,000 shares authorized, 236,620,545 and 226,063,032 shares issued and outstanding at December 31, 2024 and December 31, 2023 | 0.02a | 0.02a |
| Additional paid-in capital | 657.58a | 641.44a |
| Accumulated deficit | -308.58a | -506.26a |
| Total stockholders’ equity | 349.02a | 135.21a |
| Total liabilities and stockholders’ equity | 488.68a | 329.18a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.